A Phase 2 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX005 in Patients with, or at Risk of, Manifest Huntington’s Disease (HD) - Annexon Biosciences
	
	
	
	
	
	
	
	
	
	
















		
		

 



	

		

			

				
			

		

		
    
   

                

    





	

		

			

				

					

						
Contact Us

						

							info@annexonbio.com

							650.822.5500
						

					

					

						
Annexon, Inc.

						
1400 Sierra Point Parkway, Building C, 
2nd Floor

						Brisbane, CA 94005

					

					

							
							
					

				

				

                    
					
© 2024 Annexon, Inc.  All rights reserved.